Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

9,859 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Cell cycle phenotype-based optimization of G2-abrogating peptides yields CBP501 with a unique mechanism of action at the G2 checkpoint.
Sha SK, Sato T, Kobayashi H, Ishigaki M, Yamamoto S, Sato H, Takada A, Nakajyo S, Mochizuki Y, Friedman JM, Cheng FC, Okura T, Kimura R, Kufe DW, Vonhoff DD, Kawabe T. Sha SK, et al. Among authors: sato t, sato h. Mol Cancer Ther. 2007 Jan;6(1):147-53. doi: 10.1158/1535-7163.MCT-06-0371. Mol Cancer Ther. 2007. PMID: 17237275
Phase I studies of CBP501, a G2 checkpoint abrogator, as monotherapy and in combination with cisplatin in patients with advanced solid tumors.
Shapiro GI, Tibes R, Gordon MS, Wong BY, Eder JP, Borad MJ, Mendelson DS, Vogelzang NJ, Bastos BR, Weiss GJ, Fernandez C, Sutherland W, Sato H, Pierceall WE, Weaver D, Slough S, Wasserman E, Kufe DW, Von Hoff D, Kawabe T, Sharma S. Shapiro GI, et al. Among authors: sato h. Clin Cancer Res. 2011 May 15;17(10):3431-42. doi: 10.1158/1078-0432.CCR-10-2345. Epub 2011 Jan 10. Clin Cancer Res. 2011. PMID: 21220472 Clinical Trial.
Boromycin abrogates bleomycin-induced G2 checkpoint.
Arai M, Koizumi Y, Sato H, Kawabe T, Suganuma M, Kobayashi H, Tomoda H, Omura S. Arai M, et al. Among authors: sato h. J Antibiot (Tokyo). 2004 Oct;57(10):662-8. doi: 10.7164/antibiotics.57.662. J Antibiot (Tokyo). 2004. PMID: 15638327 Free article.
The real-world data of immune-checkpoint inhibitor combination therapy for unresectable or metastatic esophageal cancer: a multi-institutional cohort study.
Sato S, Ssuzuki T, Chinen T, Yamaguchi H, Suzuki Y, Hokamura N, Saze Z, Kono K, Takahashi K, Yano F, Kunisaki C, Kosaka T, Endo I, Ichikawa Y, Miyawaki Y, Sato H, Shimada H. Sato S, et al. Among authors: sato h. Int J Clin Oncol. 2024 Apr 28. doi: 10.1007/s10147-024-02532-0. Online ahead of print. Int J Clin Oncol. 2024. PMID: 38679627
Excimer laser for the treatment of incomplete rerepigmentation 1 year after cultured epidermal autograft use for carbon dioxide laser-ablated lesions in patients with stable vitiligo.
Kato H, Toriyama K, Enomoto Y, Kanayama Y, Yamamoto A, Sato H, Tanaka T, Inoie M, Morita A. Kato H, et al. Among authors: sato h. JAAD Case Rep. 2024 Mar 15;47:80-83. doi: 10.1016/j.jdcr.2024.02.033. eCollection 2024 May. JAAD Case Rep. 2024. PMID: 38659475 Free PMC article. No abstract available.
High N6-methyladenosine-activated TCEAL8 mRNA is a novel pancreatic cancer marker.
Hara T, Meng S, Sato H, Tatekawa S, Sasaki K, Takeda Y, Tsuji Y, Arao Y, Ofusa K, Kitagawa T, Yamada D, Takahashi H, Kobayashi S, Motooka D, Suzuki Y, Rennie S, Uchida S, Mori M, Ogawa K, Doki Y, Eguchi H, Ishii H. Hara T, et al. Among authors: sato h. Cancer Sci. 2024 Apr 24. doi: 10.1111/cas.16152. Online ahead of print. Cancer Sci. 2024. PMID: 38659235
9,859 results